 ROCKVILLE, Md., Feb. 8, 2021 PRNewswire -- REGENXBIO Inc. Nasdaq: RGNX today announced that additional positive interim data from a total of eight patients in Cohorts 1 and 2 of the ongoing Phase III trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with... 